Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

MDxHealth stock price, quote, forecast and news

MDXH.BR
BE0003844611
A0J3N3

Price

3.29
Today +/-
+0
Today %
+0 %
P

MDxHealth stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the MDxHealth stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the MDxHealth stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the MDxHealth stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze MDxHealth's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

MDxHealth Stock Price History

DateMDxHealth Price
12/15/20233.29 undefined
12/14/20233.45 undefined

MDxHealth Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into MDxHealth, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by MDxHealth from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects MDxHealth’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of MDxHealth. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into MDxHealth’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing MDxHealth’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on MDxHealth’s growth potential.

MDxHealth Revenue, EBIT and net profit per share

DateMDxHealth RevenueMDxHealth EBITMDxHealth Net Income
2027e129.96 M undefined18.07 M undefined16.62 M undefined
2026e113.21 M undefined3.96 M undefined2.67 M undefined
2025e112.2 M undefined-10.78 M undefined-9.19 M undefined
2024e83.28 M undefined-20.91 M undefined-141.4 M undefined
2023e70.75 M undefined-27.38 M undefined-180.64 M undefined
202237.05 M undefined-37.86 M undefined-44.04 M undefined
202122.24 M undefined-26.84 M undefined-29 M undefined
202018.46 M undefined-26.85 M undefined-28.66 M undefined
201911.79 M undefined-36.88 M undefined-43.1 M undefined
201828.4 M undefined-32.1 M undefined-32.45 M undefined
201740.51 M undefined-12.27 M undefined-12.29 M undefined
201629.97 M undefined-12.85 M undefined-13.17 M undefined
201517.64 M undefined-14.38 M undefined-14.47 M undefined
201411.67 M undefined-15.34 M undefined-15.26 M undefined
20137.55 M undefined-16.07 M undefined-16.18 M undefined
20125.91 M undefined-11.44 M undefined-11.53 M undefined
20113.74 M undefined-9.88 M undefined-9.67 M undefined
20103.36 M undefined-11.08 M undefined-10.93 M undefined
20093.54 M undefined-20.49 M undefined-19.89 M undefined
20084.42 M undefined-16.57 M undefined-14.91 M undefined
20073.62 M undefined-15.02 M undefined-13.66 M undefined
20063.48 M undefined-9.84 M undefined-9.25 M undefined
20053.83 M undefined-5.39 M undefined-5.32 M undefined
2004480,000 undefined-6.52 M undefined-6.45 M undefined
20030 undefined-4.52 M undefined-4.58 M undefined

MDxHealth Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200320042005200620072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e2027e
003334333571117294028111822377083112113129
-----33.33-25.00--66.6740.0057.1454.5570.5937.93-30.00-60.7163.6422.2268.1889.1918.5734.940.8914.16
--100.00100.00100.00100.00100.0066.67100.0080.0014.2945.4552.9462.0772.5057.14-38.8945.4551.35-----
003334323415918291607101900000
-4-6-5-9-15-16-20-11-9-11-16-15-14-12-12-32-36-26-26-37-27-20-10318
---166.67-300.00-500.00-400.00-666.67-366.67-300.00-220.00-228.57-136.36-82.35-41.38-30.00-114.29-327.27-144.44-118.18-100.00-38.57-24.10-8.932.6513.95
-4-6-5-9-13-14-19-10-9-11-16-15-14-13-12-32-43-28-29-44-180-141-9216
-50.00-16.6780.0044.447.6935.71-47.37-10.0022.2245.45-6.25-6.67-7.14-7.69166.6734.38-34.883.5751.72309.09-21.67-93.62-122.22700.00
1111.051.081.181.321.321.722.2133.484.134.614.995.766.268.3212.1915.8700000
-------------------------
Details

Keystats

ⓘ

Revenue and Growth

The MDxHealth Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the MDxHealth is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (k)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20032004200520062007200820092010201120122013201420152016201720182019202020212022
                                       
1.10.311.243.348.342.825.814.214.415.524.718.931.730.916.826.222.11658.515.5
00.51.50.10.70.50.81.41.62.227.51118.519.819.16.63.84.69.4
0.20.41.31.43.54.25.51.81.60.70.20.50.20.10.100.10.10.50.1
00000.10.10.10.10.10.10.20.91.41.51.91.81.22.31.92.3
5.16.30.510.60.40.40.30.30.40.50.40.40.50.60.8111.11.8
6.47.514.545.853.24832.617.81818.927.628.244.751.539.247.93123.266.629.1
0.40.70.622.521.50.80.91.10.80.71.92.32.62.12.53.757.9
000007007000000000000000
00.11.40.62.31.50.60.60000.100000000
0.60.50.30.20.12.30.10.10.10121012.815.514.47.35.13.446.2
0000000000001.11.11.11.100035.9
00000000000000000000
11.32.32.84.96.52.91.511.11.82.81316.219.217.69.88.88.490
7.48.816.848.658.154.535.519.3192029.43157.767.758.465.540.83275119.1
                                       
1219.327.553.666.471.373.114.118.125.335.537.842.845.945.953.962.876.7128.5133.5
000211.515.215.614.61925.341.753.383.1101.1101.2135.7136.3136.3153.2153.2
-5.1-12.2-15.5-13.4-28.2-40.8-61.8-14.3-23.2-34.2-52-66.9-80.9-93.5-104.9-136.3-178.5-205.9-233.7-276.9
000000000.7-0.4-0.7-0.4-0.7-0.71.2-1.2-0.9-1.3-1-0.4
00000000000000000000
6.97.11242.249.745.726.914.414.61624.523.844.352.843.452.119.75.8479.4
0.41.11.23.71.82.21.60.91.31.42.34.25.266.15.12.62.93.25.1
00002.62.34.52.22.22.52.52.74.355.86.85.75.679.1
0.10.51.91.72.12.71.71.10.5000.111.10.90.40.90.912.3
0000000000000001000000
0000000000000.40.40.40.11.23.65.31.8
0.51.63.15.46.57.27.84.243.94.8710.912.513.212.510.41316.518.3
0000000000000.40.10.50.39.812.310.338
0000000000008007006006000000
00.11.80.921.80.80.80.4000.11.41.60.700.70.71.553.5
00.11.80.921.80.80.80.4000.12.62.41.80.910.51311.891.5
0.51.74.96.38.598.654.43.94.87.113.514.91513.420.92628.3109.8
7.48.816.948.558.254.735.519.41919.929.330.957.867.758.465.540.631.875.3119.2
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of MDxHealth provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand MDxHealth's financial health and stability.

Assets

MDxHealth's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that MDxHealth must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of MDxHealth after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into MDxHealth's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20032004200520062007200820092010201120122013201420152016201720182019202020212022
-4-6-5-9-15-16-20-11-9-11-16-15-14-12-12-32-43-27-26-37
00000130000001123334
00000000000000000000
0002-2100001-3-1-6-101010-2
00002000000001128221
000000000000000001,0001,0001,000
00000000000000000000
-4-5-5-6-15-13-17-10-9-10-14-18-14-16-10-28-22-20-22-34
-100-10-30000-1-1-2-4-4-1000-4
-5-1500-20000-1-1-7-5-6-1000-29
-405010010000-50-10000-25
00000000000000000000
000000000000000081-122
105113615120091224143421042913680
10511361512009122414352104117146620
------------------1.00-1.00-1.00
00000000000000000000
1011290-3-17-9019-5120-149-4-642-43
-5.39-6.01-5.27-7.81-16.46-16.93-18.21-10.86-9.52-11.56-15.33-19.85-16.49-21.48-15.35-29.89-22.36-20.78-23.45-38.28
00000000000000000000

MDxHealth stock margins

The MDxHealth margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MDxHealth. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MDxHealth.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the MDxHealth's sales revenue. A higher gross margin percentage indicates that the MDxHealth retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the MDxHealth's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the MDxHealth's total revenue generated. When comparing the revenue margin year over year, investors can gauge the MDxHealth's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the MDxHealth. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the MDxHealth's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

MDxHealth Margin History

MDxHealth Gross marginMDxHealth Profit marginMDxHealth EBIT marginMDxHealth Profit margin
2027e51.74 %13.91 %12.79 %
2026e51.74 %3.5 %2.36 %
2025e51.74 %-9.61 %-8.19 %
2024e51.74 %-25.11 %-169.78 %
2023e51.74 %-38.71 %-255.34 %
202251.74 %-102.19 %-118.87 %
202146.81 %-120.68 %-130.4 %
202043.01 %-145.45 %-155.25 %
2019-1.19 %-312.81 %-365.56 %
201857.89 %-113.03 %-114.26 %
201773.54 %-30.29 %-30.34 %
201661.13 %-42.88 %-43.94 %
201553.06 %-81.52 %-82.03 %
201444.73 %-131.45 %-130.76 %
201323.31 %-212.85 %-214.3 %
201280.37 %-193.57 %-195.09 %
201190.11 %-264.17 %-258.56 %
201085.42 %-329.76 %-325.3 %
200992.94 %-578.81 %-561.86 %
200892.08 %-374.89 %-337.33 %
200782.87 %-414.92 %-377.35 %
200697.99 %-282.76 %-265.8 %
200596.34 %-140.73 %-138.9 %
200497.92 %-1,358.33 %-1,343.75 %
200351.74 %0 %0 %

MDxHealth Stock Sales Revenue, EBIT, Earnings per Share

The MDxHealth earnings per share therefore indicates how much revenue MDxHealth has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue MDxHealth earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates MDxHealth's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of MDxHealth’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating MDxHealth's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

MDxHealth Revenue, EBIT and net profit per share

DateMDxHealth Sales per ShareMDxHealth EBIT per shareMDxHealth Earnings per Share
2027e4.76 undefined0 undefined0.61 undefined
2026e4.15 undefined0 undefined0.1 undefined
2025e4.11 undefined0 undefined-0.34 undefined
2024e3.05 undefined0 undefined-5.18 undefined
2023e2.59 undefined0 undefined-6.62 undefined
20222.33 undefined-2.39 undefined-2.78 undefined
20211.82 undefined-2.2 undefined-2.38 undefined
20202.22 undefined-3.23 undefined-3.44 undefined
20191.88 undefined-5.89 undefined-6.88 undefined
20184.93 undefined-5.57 undefined-5.63 undefined
20178.12 undefined-2.46 undefined-2.46 undefined
20166.5 undefined-2.79 undefined-2.86 undefined
20154.27 undefined-3.48 undefined-3.5 undefined
20143.35 undefined-4.41 undefined-4.39 undefined
20132.52 undefined-5.36 undefined-5.39 undefined
20122.67 undefined-5.18 undefined-5.22 undefined
20112.17 undefined-5.74 undefined-5.62 undefined
20102.55 undefined-8.39 undefined-8.28 undefined
20092.68 undefined-15.52 undefined-15.07 undefined
20083.75 undefined-14.04 undefined-12.64 undefined
20073.35 undefined-13.91 undefined-12.65 undefined
20063.31 undefined-9.37 undefined-8.81 undefined
20053.83 undefined-5.39 undefined-5.32 undefined
20040.48 undefined-6.52 undefined-6.45 undefined
20030 undefined-4.52 undefined-4.58 undefined

MDxHealth business model

MDxHealth SA was founded in 2003 and is a publicly traded company based in Belgium, specializing in the development and marketing of molecular diagnostic tests for cancer diagnosis. The company focuses on developing tests for the diagnosis of prostate, bladder, and kidney cancer, as well as tests for monitoring the progression of these cancer types. The business model of MDxHealth is to develop state-of-the-art molecular diagnostics for cancer medicine and make them accessible to medical professionals and pathologists. The company has a strong presence in the US and Europe, and works closely with leading cancer centers and clinics to promote the use of the tests and improve their effectiveness. MDxHealth also provides support to its customers in interpreting test results and choosing the best treatment options for patients. The company has different divisions tailored to the specific needs of patients, doctors, and pathologists. The main divisions are the oncology division and the urology division. In the oncology division, MDxHealth offers various tests for prostate cancer, including the Prognostic Oncotype DX Test used for predicting the progression of prostate cancer. The urology division of MDxHealth focuses on developing tests for bladder cancer and kidney cancer. The key tests in this division include the ConfirmMDx Test used for diagnosing bladder cancer, and the SelectMDx Test used for diagnosing aggressive prostate cancer. MDxHealth also has a significant presence in genomics and personalized medicine. The company partners with the University of Miami Miller School of Medicine to research and improve the application of genetic tests in cancer diagnosis and treatment. MDxHealth also collaborates closely with other leading research institutions and cancer centers to drive innovation in molecular diagnostics. Overall, MDxHealth offers a wide range of molecular diagnostic tests for cancer diagnosis and monitoring. The company has a strong presence in the US and Europe, and works closely with leading cancer centers and clinics to promote the use of the tests and improve their effectiveness. MDxHealth is a key player in the field of molecular diagnostics and has the potential to improve the lives of cancer patients worldwide. MDxHealth is one of the most popular companies on Eulerpool.com.

MDxHealth SWOT Analysis

Strengths

MDxHealth SA benefits from a strong market position in the field of molecular diagnostics. The company has developed innovative diagnostic tests that provide valuable information for doctors and patients in the diagnosis and treatment of various types of cancer. This expertise has helped MDxHealth establish a solid reputation and gain the trust of healthcare professionals.

Furthermore, MDxHealth has a diverse portfolio of diagnostic products, catering to different cancer types. This diversity minimizes the company's dependency on a single product, allowing for a more stable revenue stream. Additionally, MDxHealth's tests are non-invasive and often provide results faster than traditional tests, offering a competitive advantage in terms of convenience for patients and healthcare providers.

Weaknesses

One major weakness for MDxHealth is its dependence on regulatory approvals for its products. The diagnostic industry is heavily regulated, and delays in obtaining necessary approvals can hamper the company's ability to successfully commercialize its tests. This dependency exposes MDxHealth to potential delays and uncertainties, impacting its market presence and competitive standing.

Additionally, MDxHealth faces significant competition from other companies in the molecular diagnostics industry. Rival firms may develop similar tests, reducing MDxHealth's market share and potentially eroding its pricing power. The company needs to continuously innovate and enhance its testing capabilities to stay ahead of competitors.

Opportunities

MDxHealth has the opportunity to expand its market presence by entering new geographic regions. Currently, the company mainly operates in Europe and the United States, but it could explore partnerships and licensing agreements to enter untapped markets in Asia and other regions. This expansion would provide access to a larger patient population and increase potential revenues.

Moreover, with the growing focus on personalized medicine, MDxHealth can capitalize on advancements in genomics and other technologies to develop new diagnostic tests tailored to individual patients. By leveraging these opportunities, MDxHealth can stay at the forefront of molecular diagnostics and provide more targeted and effective solutions for cancer detection and treatment.

Threats

MDxHealth faces the threat of reimbursement challenges. Given the evolving healthcare landscape and cost containment measures, there is a risk that payers, such as insurance companies and government healthcare systems, may limit coverage or reimbursement rates for diagnostic tests. This could negatively impact MDxHealth's revenue and profitability.

Additionally, the molecular diagnostics industry is subject to rapid technological advancements and changing customer needs. MDxHealth needs to continuously invest in research and development to stay ahead of these changes. Failure to adapt to emerging trends and technologies could result in the company's products becoming obsolete and losing market share to more innovative competitors.

MDxHealth Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

MDxHealth historical P/E ratio, EBIT, and P/S ratio.

MDxHealth shares outstanding

The number of shares was MDxHealth in 2023 — This indicates how many shares 15.87 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue MDxHealth earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates MDxHealth's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of MDxHealth’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating MDxHealth's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

MDxHealth Stock splits

In MDxHealth's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for MDxHealth.

MDxHealth list of shareholders

%
Name
Stocks
Change
Date
85.35579 % Bleichroeder LP23,291,97419,091,9746/30/2023
45.96081 % Valiance Advisors LLP12,541,832-4,884,3526/30/2023
4.99036 % BNP Paribas Asset Management Belgium S.A.1,361,77509/30/2023
26.26332 % Marien (Rudi)7,166,761-3,923,4966/30/2023
100.27813 % MVM Partners LLP27,363,997-18,140,5876/30/2023
0.07139 % Dimensional Fund Advisors, Ltd.19,48008/31/2023
0.03091 % Dimensional Fund Advisors, L.P.8,43406/30/2023
1

MDxHealth Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Laboratory Corp Stock
Laboratory Corp
SupplierCustomer0,600,55-0,380,650,430,50
Takara Bio Stock
Takara Bio
SupplierCustomer0,190,21-0,340,750,850,49
Teva Pharmaceutical Inds Stock
Teva Pharmaceutical Inds
SupplierCustomer0,11-0,06-0,24-0,110,580,27
QIAGEN Stock
QIAGEN
SupplierCustomer-0,020,29-0,740,420,26
Epigenomics Stock
Epigenomics
SupplierCustomer-0,22-0,14-0,230,430,96-0,44
EXACT Sciences Stock
EXACT Sciences
SupplierCustomer-0,570,13-0,360,460,920,56
1

Most common questions regarding MDxHealth

What values and corporate philosophy does MDxHealth represent?

MDxHealth SA represents values of innovation, integrity, and excellence. The company is dedicated to transforming the field of molecular diagnostics by developing and commercializing advanced tests that contribute to personalized medicine. With a commitment to improving patient outcomes, MDxHealth SA focuses on precision medicine solutions for cancer diagnosis and treatment. Through their groundbreaking technologies and collaborative approach, the company strives to provide accurate and timely information to healthcare professionals, empowering them to make informed decisions for their patients. MDxHealth SA's corporate philosophy centers around patient-centricity, scientific rigor, and global accessibility, making them a leading player in the world of molecular diagnostics.

In which countries and regions is MDxHealth primarily present?

MDxHealth SA is primarily present in various countries and regions across the globe. The company has a strong international presence and operates in multiple key markets. Some of the primary countries and regions that MDxHealth SA focuses on include the United States, Europe (including Belgium, Germany, France, and the United Kingdom), as well as other parts of the world. This global presence allows the company to reach a wide customer base and expand its market reach. With its strategic presence in these countries and regions, MDxHealth SA aims to provide its innovative diagnostic solutions and personalized medicine services to a diverse range of patients and healthcare professionals.

What significant milestones has the company MDxHealth achieved?

MDxHealth SA, a leading healthcare company, has achieved several significant milestones. One of the notable accomplishments is the FDA approval of their prostate cancer diagnostic test, ConfirmMDx®, which has revolutionized the detection process. Furthermore, the company successfully launched SelectMDx®, a non-invasive urine-based test that aids in identifying patients at high risk of aggressive prostate cancer. MDxHealth SA's collaboration with multiple renowned institutions and experts in the field has contributed to their success in driving innovation and improving patient outcomes. With their consistent commitment to research and development, MDxHealth SA continues to pave the way for groundbreaking advancements in oncology.

What is the history and background of the company MDxHealth?

MDxHealth SA is a biotechnology company based in Belgium. Founded in 2003, MDxHealth focuses on developing and commercializing molecular diagnostic tests for cancer. The company primarily focuses on prostate cancer and offers a range of tests, including ConfirmMDx and SelectMDx, which provide insights into the risk and aggressiveness of the disease. MDxHealth's tests are non-invasive and leverage advanced epigenetic technologies to provide accurate and actionable results. With a strong emphasis on research and development, MDxHealth works towards improving patient care and contributing to early detection and personalized treatment options for cancer patients.

Who are the main competitors of MDxHealth in the market?

MDxHealth SA faces competition from various companies in the market. Some of its main competitors include Exact Sciences Corporation, Genomic Health Inc., and Myriad Genetics Inc. These companies also operate in the field of molecular diagnostics and offer similar products and services. However, MDxHealth SA distinguishes itself through its innovative technology, extensive testing portfolio, and strong expertise in the field. Engaging in rigorous research and development, MDxHealth SA continuously strives to maintain its competitive edge in the market.

In which industries is MDxHealth primarily active?

MDxHealth SA is primarily active in the healthcare industry, specializing in molecular diagnostics. As a leading company in precision medicine, MDxHealth SA focuses on developing and commercializing innovative tests that aid physicians in diagnosing and monitoring patients with urological diseases, including prostate cancer. With their advanced molecular diagnostic technologies, MDxHealth SA plays a crucial role in providing accurate and actionable information for personalized treatment decisions, ultimately improving patient outcomes in the healthcare sector.

What is the business model of MDxHealth?

The business model of MDxHealth SA revolves around providing innovative molecular diagnostic solutions to improve the diagnosis and treatment of cancer. The company primarily focuses on developing and commercializing diagnostic tests that aid in the early detection, prognosis, and monitoring of various types of cancers, including prostate, bladder, and lung cancer. MDxHealth offers its diagnostic tests through a global network of clinical laboratories and medical institutions. By offering accurate and actionable diagnostic information, MDxHealth aims to support healthcare professionals in making informed treatment decisions and ultimately improving patient outcomes. MDxHealth's business model underscores its commitment to advancing personalized medicine and precision oncology.

What is the P/E ratio of MDxHealth 2024?

The MDxHealth P/E ratio is -0.37.

What is the P/S ratio of MDxHealth 2024?

The MDxHealth P/S ratio is 0.63.

What is the AlleAktien quality score of MDxHealth?

The AlleAktien quality score for MDxHealth is 6/10.

What is the revenue of MDxHealth 2024?

The expected MDxHealth revenue is 83.28 M USD.

How high is the profit of MDxHealth 2024?

The expected MDxHealth profit is -141.4 M USD.

What is the business model of MDxHealth

MDxHealth SA is a Belgian biotechnology company specializing in the development of in vitro diagnostics (IVDs) for personalized medicine. The company aims to improve the diagnosis and therapy of cancer by providing more precise and effective tools. It is based in Herstal, with sales offices in Europe, the USA, and Asia. The company operates in three business areas: diagnostics, pharmaceuticals, and laboratory services. In terms of diagnostics, MDxHealth SA develops and distributes biomarker tests for the diagnosis of prostate, bladder, and kidney cancer. These tests help doctors identify patients with more aggressive forms of cancer and determine the most appropriate treatment. In the pharmaceutical area, the company focuses on the development of therapies for prostate cancer and has partnered with Dutch pharmaceutical company Argenx to advance the development of antibodies for the treatment of prostate cancer. The goal of this collaboration is to develop personalized therapy based on individual patient biomarker profiles. MDxHealth SA's laboratory services division offers diagnostic tests and consulting services to patients and doctors. The company has its own clinical laboratory in the USA where the tests it develops are analyzed and evaluated. MDxHealth SA also provides training and education for medical professionals to ensure a wider use and better interpretation of its tests. Some of the company's key products include the SelectMDx and ConfirmMDx tests. SelectMDx is a non-invasive test for the diagnosis of prostate cancer based on the analysis of urine samples. The test provides doctors with an easy way to distinguish between patients at high and low risk of prostate cancer. ConfirmMDx is another diagnostic test for identifying patients who may require a repeat prostate biopsy. The test allows doctors to detect prostate cancer with greater accuracy and avoid unnecessary biopsies. MDxHealth SA works closely with medical institutions, associations, and authorities to raise awareness of its tests and technologies and promote personalized medicine. The company also maintains close relationships with research institutions and universities to advance its research activities and develop innovative solutions to improve cancer diagnosis and therapy. Overall, MDxHealth SA's business model is focused on providing better diagnostic tests and personalized therapies for cancer patients. The company combines research and development, sales, and consulting services to establish and sell its products and services in the market.

What is the MDxHealth dividend?

MDxHealth pays a dividend of 0 USD distributed over payouts per year.

How often does MDxHealth pay dividends?

The dividend cannot currently be calculated for MDxHealth or the company does not pay out a dividend.

What is the MDxHealth ISIN?

The ISIN of MDxHealth is BE0003844611.

What is the MDxHealth WKN?

The WKN of MDxHealth is A0J3N3.

What is the MDxHealth ticker?

The ticker of MDxHealth is MDXH.BR.

How much dividend does MDxHealth pay?

Over the past 12 months, MDxHealth paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MDxHealth is expected to pay a dividend of 0 USD.

What is the dividend yield of MDxHealth?

The current dividend yield of MDxHealth is .

When does MDxHealth pay dividends?

MDxHealth pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of MDxHealth?

MDxHealth paid dividends every year for the past 0 years.

What is the dividend of MDxHealth?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is MDxHealth located?

MDxHealth is assigned to the 'Health' sector.

Wann musste ich die Aktien von MDxHealth kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of MDxHealth from 9/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.

When did MDxHealth pay the last dividend?

The last dividend was paid out on 9/12/2024.

What was the dividend of MDxHealth in the year 2023?

In the year 2023, MDxHealth distributed 0 USD as dividends.

In which currency does MDxHealth pay out the dividend?

The dividends of MDxHealth are distributed in USD.

All fundamentals about MDxHealth

Our stock analysis for MDxHealth Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MDxHealth Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.